Nimotuzumab (also known as h-R3) is a humanized monoclonal antibody against EGFR, which has been proven to have essential anti-tumor functions both in vitro and in vivo by inhibiting proliferation, affecting angiogenesis, and promoting apoptosis8,9. This evidence concerns the gene EGFR and neoplasm.